A multi-centre, randomised, dose-ascending, double-blind, placebo-controlled, four-way incomplete block crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat administration of three inhaled doses (300, 600, and 1200 mcg once daily) of GSK159802 in asthmatic patients.

Trial Profile

A multi-centre, randomised, dose-ascending, double-blind, placebo-controlled, four-way incomplete block crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat administration of three inhaled doses (300, 600, and 1200 mcg once daily) of GSK159802 in asthmatic patients.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2011

At a glance

  • Drugs GSK 159802; Salmeterol
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 21 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top